Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 240+ employees, R&D laboratories of 11000 m2 and 300+ clients and partners all around the world.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
Cureline, Inc. is a global contract research organization (CRO) and a commercial biobank supporting preclinical research in oncology, hematology, immune-oncology and various other therapeutic areas (Cardio-vascular, metabolic, neuro-degenerative, infectious and inherited conditions) to the pharmaceutical, biotechnology, and medical device industries worldwide since 2003.
Talem Therapeutics is a biotherapeutic company and a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) that leverages IPA’s antibody discovery and development expertise combined with AI/bioinformatics to generate valuable assets (best-in-class / first-in-class) for out-licensing and co-development. Talem's experts focus on next generation antibodies from target validation through IND-Readiness (indication agnostic).